YIL058W Antibody

What is the YIL058W protein and what do we currently know about its function?

YIL058W refers to a putative uncharacterized protein in Saccharomyces cerevisiae (strain 204508/S288c), commonly known as baker's yeast . Despite being identified in the yeast genome sequence, this protein's precise function remains largely unknown. Based on sequence analysis, it belongs to a category of proteins with no clear functional domains that have been definitively characterized. Researchers investigating this protein often use antibodies as tools to elucidate its potential role in cellular processes.

What validation criteria should be applied when selecting a YIL058W antibody?

Validation of antibodies targeting uncharacterized proteins like YIL058W requires special attention. Based on recommendations from the International Working Group for Antibody Validation, researchers should apply multiple validation pillars, including:

• Genetic validation - Testing the antibody in systems where the target protein is absent (knockout strains) or significantly reduced (knockdown approaches)

• Orthogonal validation - Confirming protein expression using antibody-independent methods such as mass spectrometry or RNA-seq

• Independent antibody verification - Using multiple antibodies targeting different epitopes of YIL058W to confirm specificity

• Expression validation - Demonstrating signal correlation with expected expression patterns

• Immunoprecipitation followed by mass spectrometry - To confirm the identity of the precipitated protein

For YIL058W specifically, validation is crucial since it's an uncharacterized protein with potential homologs. Researchers should be particularly vigilant about cross-reactivity with similar yeast proteins and should always run appropriate negative controls.

What are the recommended applications for YIL058W antibodies in yeast research?

YIL058W antibodies have been validated for several standard research applications, specifically:

• Western Blot (WB) - For detecting denatured YIL058W protein from yeast lysates

• Enzyme-Linked Immunosorbent Assay (ELISA) - For quantitative measurement of YIL058W in solution

• Immunoprecipitation (IP) - For isolating YIL058W and associated proteins

• Immunofluorescence (IF) - For determining subcellular localization (though additional validation is recommended)

Each application requires specific optimization. For Western blots, polyclonal YIL058W antibodies typically recognize a band at the expected molecular weight (verify with the antibody datasheet for specific product). For immunofluorescence, additional validation steps are critical to ensure signal specificity.

How can I properly design experiments to study YIL058W protein-protein interactions?

Studying protein-protein interactions involving YIL058W requires careful experimental design. Consider the following methodological approach:

• Co-immunoprecipitation (Co-IP): Use purified YIL058W antibody coupled to agarose or magnetic beads to pull down YIL058W along with interacting partners.

  • Critical controls: Include a non-specific IgG control pulldown and lysate from YIL058W knockout strains.

  • Validation: Confirm identity of pulled-down proteins via mass spectrometry rather than relying solely on antibody detection.

• Proximity-based labeling: Consider BioID or APEX2 fusion to YIL058W for identifying proximal proteins in living cells.

  • Advantage: Can identify transient or weak interactions not preserved in Co-IP.

  • Implementation: Create tagged YIL058W expression constructs and verify expression with the antibody before proceeding.

• Yeast two-hybrid assays: Complementary approach to identify direct binding partners.

  • Verification: Confirm interactions identified via Y2H using reciprocal Co-IP with YIL058W antibody.

When reporting results, present complete datasets including negative results and all controls. Avoid overinterpretation from single experimental approaches; instead, build confidence through multiple methods targeting the same interaction.

What strategies can address non-specific binding issues with YIL058W antibodies?

Non-specific binding is a common challenge with antibodies against uncharacterized proteins. Implement these methodological solutions:

• Optimized blocking strategies:

  • Test multiple blocking agents (BSA, milk, commercial blockers)

  • Extended blocking times (2-3 hours at room temperature or overnight at 4°C)

  • Addition of 0.1-0.5% Triton X-100 to reduce hydrophobic interactions

• Antibody dilution optimization:

  • Perform titration experiments (typically starting from 1:500 to 1:5000)

  • Document signal-to-noise ratio at each dilution

• Epitope competition assays:

  • Pre-incubate antibody with excess purified antigen or antigenic peptide

  • Observe elimination of specific signal while non-specific binding persists

• Cross-adsorption technique:

  • Pre-incubate antibody with lysates from YIL058W knockout strains

  • Remove antibodies recognizing epitopes present in knockout cells

Based on antibody validation surveys, approximately 65% of antibodies targeting specific proteins demonstrate off-target binding . This underscores the importance of rigorous controls, particularly when working with antibodies against uncharacterized proteins like YIL058W.

How can I quantitatively analyze YIL058W expression across different experimental conditions?

Quantitative analysis of YIL058W expression requires careful experimental design and appropriate controls. Follow this methodological framework:

• Western blot quantification:

  • Use a loading control protein with expression unaffected by your experimental conditions

  • Apply gradient loading to ensure linearity of signal

  • Employ digital image analysis software with background subtraction

  • Present data as ratio of YIL058W to loading control

• ELISA-based quantification:

  • Develop a standard curve using purified recombinant YIL058W

  • Ensure sample dilutions fall within the linear range of the standard curve

  • Perform technical triplicates and biological replicates

• Flow cytometry (for tagged proteins or permeabilized cells):

  • Include fluorescence-minus-one (FMO) controls

  • Standardize with calibration beads for consistent measurements

  • Report median fluorescence intensity (MFI) rather than mean

Sample data format for reporting YIL058W expression changes:

When analyzing expression changes, consider both statistical and biological significance. Small but statistically significant changes may not always translate to biological impact.

What extraction methods yield optimal results for detecting YIL058W in different applications?

The extraction method significantly impacts the detection of yeast proteins like YIL058W. Based on experimental data, these methodological approaches yield optimal results:

• For Western blot applications:

  • Mechanical disruption (glass beads) in buffer containing:

    • 50 mM Tris-HCl (pH 7.5)

    • 150 mM NaCl

    • 1% Triton X-100

    • 10% glycerol

    • Protease inhibitor cocktail

  • Inclusion of 2% SDS for complete denaturation

  • Heat samples at 95°C for 5 minutes

• For immunoprecipitation:

  • Gentler lysis using:

    • 20 mM HEPES (pH 7.4)

    • 150 mM KCl

    • 0.5% NP-40

    • Protease and phosphatase inhibitors

  • Avoid SDS or harsh detergents that may disrupt protein-protein interactions

• For subcellular fractionation:

  • Enzymatic cell wall removal using zymolyase followed by gentle mechanical disruption

  • Differential centrifugation to separate subcellular compartments

  • Verify fraction purity using established compartment markers

Extraction efficiency comparison data:

Regardless of method, process samples quickly and maintain cold temperatures throughout to minimize protein degradation.

How can I establish reproducible Western blot protocols for YIL058W detection?

Reproducible Western blot protocols for YIL058W detection require attention to several critical factors:

• Sample preparation optimization:

  • Standardize protein extraction method (see question 3.1)

  • Determine optimal protein concentration (typically 20-50 μg total protein)

  • Include appropriate controls: wild-type and YIL058W deletion strains

• Gel separation parameters:

  • Select gel percentage based on YIL058W molecular weight (10-12% for most yeast proteins)

  • Run at constant voltage (100-120V) for consistent separation

  • Include molecular weight markers on both sides of the gel

• Transfer optimization:

  • Use wet transfer for complete transfer of yeast proteins

  • Standard transfer conditions: 100V for 1 hour or 30V overnight at 4°C

  • Verify transfer efficiency with reversible staining (Ponceau S)

• Antibody incubation protocol:

  • Primary antibody: 1:1000 dilution in TBST with 5% BSA, overnight at 4°C

  • Washing: 3 × 10 minutes with TBST

  • Secondary antibody: 1:5000 dilution, 1 hour at room temperature

  • Final washing: 3 × 15 minutes with TBST

Common troubleshooting for YIL058W Western blots:

Document all protocol details meticulously for reproducibility. Consider using automated Western blot systems when available for enhanced consistency.

What controls are essential when using YIL058W antibodies in research applications?

Proper controls are crucial for interpreting results with YIL058W antibodies. Essential controls include:

• Genetic controls:

  • YIL058W knockout strain - Must show absence of signal

  • YIL058W overexpression strain - Should show increased signal intensity

  • Wild-type strain - Baseline expression level

• Antibody controls:

  • Isotype control (non-specific IgG from same species)

  • Peptide competition assay - Pre-incubate antibody with immunizing peptide

  • Secondary antibody only - To detect non-specific binding

• Procedural controls:

  • Loading control for Western blots (e.g., Pgk1, GAPDH)

  • Positive control (known condition that affects YIL058W expression)

  • Technical replicates to assess method variability

• Cross-validation controls:

  • Orthogonal detection method (e.g., mass spectrometry)

  • Independent antibody targeting different epitope

  • Tagged YIL058W construct (if available)

Implementation of these controls should be systematic and reported transparently. As noted in antibody validation literature, approximately 65-70% of antibodies show some level of non-specific binding, making proper controls non-negotiable for reliable research .

How can modern protein analysis technologies complement YIL058W antibody-based detection?

Modern protein analysis technologies offer powerful complementary approaches to antibody-based detection of YIL058W:

• Mass spectrometry-based approaches:

  • Targeted proteomics (PRM/MRM) for absolute quantification

  • Global proteomics for analyzing YIL058W in broader pathway context

  • Implementation: Develop unique peptide markers specific to YIL058W

• Proximity labeling methods:

  • BioID or TurboID fused to YIL058W for identifying interacting proteins

  • APEX-based approaches for temporal interaction mapping

  • Advantage: Identifies proteins in native cellular environment

• CRISPR-based tagging strategies:

  • Endogenous tagging with fluorescent proteins or epitope tags

  • Facilitates live-cell imaging and chromatin immunoprecipitation

  • Verification: Compare antibody signal with tag-based detection

• Single-cell analysis technologies:

  • Mass cytometry (CyTOF) for high-dimensional protein analysis

  • Single-cell proteomics for heterogeneity assessment

  • Benefit: Reveals cell-to-cell variation masked in population averages

Complementary technology comparison:

The integration of these complementary approaches with traditional antibody-based methods strengthens research validity through technological triangulation.

How should I design experiments to investigate YIL058W localization in yeast cells?

Investigating YIL058W subcellular localization requires a multi-faceted experimental design:

• Immunofluorescence microscopy:

  • Fix cells with 4% paraformaldehyde for 15 minutes

  • Permeabilize with 0.1% Triton X-100 for 5 minutes

  • Block with 3% BSA for 30 minutes

  • Incubate with YIL058W antibody (1:500 dilution) overnight at 4°C

  • Essential controls: YIL058W knockout strain, secondary antibody only

  • Co-staining with compartment markers (e.g., DAPI for nucleus, Sec61 for ER)

• Fluorescent protein tagging:

  • C-terminal and N-terminal GFP fusions (verify function is maintained)

  • Time-lapse imaging for dynamic localization studies

  • Verification: Compare localization pattern with antibody staining

• Biochemical fractionation:

  • Separate cellular components via differential centrifugation

  • Analyze fractions by Western blot using YIL058W antibody

  • Include markers for different cellular compartments

  • Quantify relative distribution across fractions

• Electron microscopy with immunogold labeling:

  • Ultimate resolution for precise localization

  • Multiple antibody dilutions to optimize signal-to-noise ratio

  • Quantitative analysis of gold particle distribution

Analysis framework for localization studies:

Report localization data with statistical analysis of colocalization coefficients and include representative images alongside quantification.

What approaches can help determine if YIL058W undergoes post-translational modifications?

Investigating post-translational modifications (PTMs) of YIL058W requires specialized methodological approaches:

• Modification-specific detection:

  • Use phospho-specific antibodies if available

  • Employ Phos-tag gels to detect phosphorylated forms

  • Apply lectins (ConA, WGA) to detect glycosylation

  • Ubiquitination detection via specialized antibodies or tagged ubiquitin

• Mass spectrometry-based PTM mapping:

  • Immunoprecipitate YIL058W using validated antibody

  • Perform tryptic digestion and analyze by LC-MS/MS

  • Use neutral loss scanning for phosphorylation

  • Employ electron transfer dissociation (ETD) for glycosylation analysis

• Modification-inducing conditions:

  • Treat cells with phosphatase inhibitors to preserve phosphorylation

  • Apply proteasome inhibitors to detect ubiquitination

  • Test stress conditions that might trigger modifications

  • Compare migration patterns by Western blot before/after treatment

• Site-directed mutagenesis:

  • Identify potential modification sites via bioinformatics

  • Create point mutations (e.g., S→A for phosphorylation sites)

  • Analyze functional consequences of preventing modification

Sample PTM analysis workflow:

• Predict potential PTM sites using tools like NetPhos, UbPred

• Immunoprecipitate YIL058W from cells under various conditions

• Analyze by Western blot for mobility shifts

• Confirm via mass spectrometry and report modification sites precisely

When reporting PTM data, include spectra, sequence coverage, and confidence scores for each identified modification.

How can I effectively use YIL058W antibodies in chromatin immunoprecipitation (ChIP) experiments?

While YIL058W is not known to be a DNA-binding protein, if research suggests nuclear localization or chromatin association, ChIP experiments may be warranted. The methodological approach should include:

• ChIP protocol optimization:

  • Crosslinking: Test different formaldehyde concentrations (0.5-1.5%)

  • Sonication: Optimize to achieve 200-500bp fragments

  • Antibody amount: Typically 2-5μg per IP reaction

  • Incubation time: 4-16 hours at 4°C with rotation

• Essential controls:

  • Input DNA (pre-immunoprecipitation sample)

  • Mock IP (with non-specific IgG)

  • YIL058W knockout strain

  • Positive control locus (if known interaction exists)

  • Negative control locus (highly transcribed gene unlikely to interact)

• Analysis methods:

  • ChIP-qPCR for targeted analysis of suspected binding sites

  • ChIP-seq for genome-wide binding profile

  • Data normalization to input and IgG control

• Validation approaches:

  • Reciprocal ChIP with known interacting factors

  • DNA affinity pulldown with potential target sequences

  • Compare ChIP results with tagged version of YIL058W

When implementing ChIP for proteins without established DNA binding, stringent controls are particularly important to distinguish specific from non-specific chromatin associations.

How can alternative antibody generation systems be applied to improve YIL058W antibody quality?

Recent advances in antibody technology offer opportunities to develop improved YIL058W antibodies:

• Yeast-based antibody systems:

  • Utilize yeast display platforms for antibody selection

  • Advantage: Can select antibodies in a yeast cell environment

  • Implementation: Create a library of 500 million potential antibodies and screen against purified YIL058W

  • Process takes 3-6 weeks versus 3-6 months for traditional methods

• Nanobody development:

  • Single-domain antibodies derived from camelid antibodies

  • Smaller size allows access to restricted epitopes

  • Can be produced recombinantly in microbial systems

  • Applications: Super-resolution microscopy, intracellular targeting

• Recombinant antibody frameworks:

  • Use phage display to select antibody fragments

  • Engineer for increased specificity and reduced cross-reactivity

  • Consistent production without batch-to-batch variation

  • Potential for humanized versions for therapeutic applications

As noted in Harvard Medical School research, yeast-based antibody platforms have demonstrated success rates comparable to traditional immunization while providing faster results and more consistent production . These systems could be particularly valuable for generating antibodies against challenging targets like uncharacterized yeast proteins.

What considerations are important when designing multiplexed assays involving YIL058W antibodies?

Multiplexed detection involving YIL058W antibodies requires careful assay design:

• Antibody compatibility assessment:

  • Test for cross-reactivity between primary antibodies

  • Ensure secondary antibody specificity when using multiple primaries

  • Validate that detection of one target doesn't interfere with others

• Spectral separation strategies:

  • For fluorescence-based methods, ensure adequate separation between fluorophores

  • Consider spectral unmixing for closely overlapping signals

  • Sequential detection may be necessary for problematic combinations

• Quantitative considerations:

  • Establish individual standard curves for each target

  • Validate that multiplexed detection yields equivalent results to singleplex

  • Account for potential signal suppression in high-density arrays

• Technological platforms:

  • Suspension arrays (e.g., Luminex) for soluble protein detection

  • Mass cytometry for single-cell protein analysis without fluorescence limitations

  • Sequential immunoblotting with antibody stripping between rounds

Validation metrics for multiplexed assays:

When reporting multiplexed data, include comprehensive validation metrics alongside experimental results.